Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …

The aim of this study to develop galactosylated erlotinib liposomes for treatment of lung
cancer. The liposomes were prepared by using solvent evaporation method. Various …

Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …

Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …

Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

The current study was aimed to prepare a molecular complex of erlotinib (ERL) with
phospholipid (PC) for enhancement of solubility and thus bioavailability, therapeutic efficacy …

The present study was aimed to develop and optimize nanoliposomes of gefitinib for
effective tumor targeting. Central composite design was used to study the effect of …

Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …

Erlotinib is a tyrosine kinase inhibitor and it can treat tumors, such as pancreatic and locally
advanced lung cancer or metastatic cancer. The traditional formulation of erlotinib currently …